

STOP

Before using this product, please read the Limited Use License statement below:

Important Limited Use License information for pFUSE-Lucia-mG2a-Fc

The purchase of the pFUSE-Lucia-mG2a-Fc vector conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes.

The buyer may transfer information or materials made through the use of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) not to transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes.

Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic, or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research.

If the purchaser is unwilling to accept the limitations of this limited use statement, InvivoGen is willing to accept return of the product with a full refund. The product must be returned in resaleable condition. For information on purchasing a license to this product for purposes other than research, contact InvivoGen, 10515 Vista Sorrento Parkway San Diego, CA 92121 USA. Tel: 858-457-5873 Fax: 858-457-5843.

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Asia: +852 3-622-34-80

E-mail: info@invivogen.com



pFUSE-Lucia-mG2a-Fc

Plasmid designed for the expression of a Lucia-Fc fusion protein

Catalog # pfuse-mg2alc

For research use only

Version 22H31-MM

PRODUCT INFORMATION

Content:

- 20 µg of pFUSE-Lucia-mG2a-Fc plasmid provided as lyophilized DNA
- 1 ml of Zeocin® (100 mg/ml)

Storage and Stability:

- Product is shipped at room temperature.
- Lyophilized DNA should be stored at -20 °C.
- Resuspended DNA should be stored at -20 °C and is stable for 1 year.
- Store Zeocin® at 4 °C or at -20 °C. The expiry date is specified on the product label.

Quality control:

- Plasmid construct has been confirmed by restriction analysis and sequencing.
- Plasmid DNA was purified by ion exchange chromatography and lyophilized.

GENERAL PRODUCT USE

pFUSE-Fc is a family of plasmids developed to facilitate the construction of Fc-fusion proteins by fusing the effector region of a protein to the Fc region of an immunoglobulin G (IgG).

pFUSE-Fc plasmids yield high levels of Fc-fusion proteins. The level of expression is usually in the µg/mL range. They can be transfected in a variety of mammalian cells, including myeloma cell lines, CHO cells, monkey COS cells and human embryonic kidney (HEK)293 cells, cells that are commonly used in protein purification systems.

pFUSE-Lucia-mG2a-Fc plasmids allow the production of Lucia-Fc fusion proteins. This plasmid can be used to make recombinant Lucia-Fc fusion proteins or can be used as a transfection control in experiments with other pFUSE-hFc constructs. Quantification of Lucia-Fc expression can be determined utilizing InvivoGen's QUANTI-Luc™ (rep-qlc1 or rep-qlc2).

PLASMID FEATURES

- **Lucia luciferase** is a secreted coelenterazine-utilizing luciferase reporter protein with advantageous characteristics when associated with Fc-fusion proteins. It possesses superior carrier ability for excellent secretion of the chimeric protein. It provides a simple means to screen for recombinant clones and it minimally affects the activity of the protein of interest.

- **mIgG2a Fc (mouse):** The Fc region comprises the CH2 and CH3 domains of the IgG heavy chain and the hinge region. The hinge serves as a flexible spacer between the two parts of the Fc-fusion protein, allowing each part of the molecule to function independently. Mouse IgG2a displays high ADCC and CDC.

- **hEF1-HTLV prom** is a composite promoter comprising the Elongation Factor-1α (EF-1α) core promoter¹ and the R segment and part of the U5 sequence (R-U5') of the Human T-Cell Leukemia Virus (HTLV) Type 1 Long Terminal Repeat². The EF-1α promoter exhibits a strong activity and yields long lasting expression of a transgene *in vivo*. The R-U5' has been coupled to the EF-1α core promoter to enhance stability of RNA.

- **MCS:** The multiple cloning site contains several restriction sites that are compatible with many other enzymes, thus facilitating cloning.

- **SV40 pAn:** the Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions resulting in high levels of steady-state mRNA³.

- **ori:** a minimal *E. coli* origin of replication to limit vector size, but with the same activity as the longer Ori.

- **CMV enh/hFerL prom:** This composite promoter combines the human cytomegalovirus immediate-early gene 1 enhancer and the core promoter of the human ferritin light chain gene. This ubiquitous promoter drives the expression of the Zeocin®-resistance gene in mammalian cells.

- **EM2KC** is a bacterial promoter that enables the constitutive expression of the antibiotic resistance gene in *E. coli*. EM2KC is located within an intron and is spliced out in mammalian cells.

- **Zeo:** Resistance to Zeocin® is conferred by the *Sh ble* gene from *Streptoalloteichus hindustanus*. The same resistance gene confers selection in both mammalian cells and *E. coli*.

- **βGlo pAn:** The human beta-globin 3'UTR and polyadenylation sequence allows efficient arrest of the transgene transcription⁴.

1. Kim DW *et al.* 1990. Use of the human elongation factor 1 alpha promoter as a versatile and efficient expression system. *91(2):217-23*.

2. Takebe Y. *et al.* 1988. SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. *Mol Cell Biol.* 8(1):466-72.

3. Carswell S. & Alwine JC. 1989. Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences. *Mol Cell Biol.* 9(10):4248-58.

4. Yu J. & Russell JE. 2001. Structural and functional analysis of an mRNP complex that mediates the high stability of human beta-globin mRNA. *Mol Cell Biol.* 21(17):5879-88.

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Asia: +852 3-622-34-80

E-mail: info@invivogen.com

METHODS

Plasmid resuspension

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile H₂O. Store resuspended plasmid at -20 °C.

Plasmid amplification and cloning

Plasmid amplification and cloning can be performed in *E. coli* GT116 other commonly used laboratory *E. coli* strains, such as DH5α.

Zeocin® usage

This antibiotic can be used for *E. coli* at 25 µg/ml in liquid or solid media and at 50-200 µg/ml to select Zeocin®-resistant mammalian cells.

RELATED PRODUCTS

Product	Catalog Code
ChemiComp GT116	gt116-11
QUANTI-Luc™	rep-qlc1
Zeocin®	ant-zn-1

TECHNICAL SUPPORT


InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Asia: +852 3-622-34-80

E-mail: info@invivogen.com



PvuI (11)
SgfI (11)
 1 GGATCTGCATCGCTCCGGTCCCGTCAGTGGGAGAGCGCACATCGCCACAGTCCCCGAGAAGTTGGGGGAGGGGTCGGCAATTGAACGGGTGCCTA
 101 GAGAAGGTGGCGGGGTAAGTGGGAAAGTATGTCGTGACTGGCTCCGCTTTTCCGAGGGTGGGGGAGAACCCTATATAAGTGCAGTAGTCGCC

HindIII (246)
Psp1406I (205) **PvuII (242)** **Bsu36I (293)**
 201 GTGAACGTTCTTTTCGCAACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTCTTCACGGCCCGCCCTACCTGAGGCC
 301 GCCATCCACGGCGTTGAGTCGGCTTCTGCCGCTCCCGCTGTGGTGCCTCTGAAGTCCGCTCCGCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACC
 401 GGGCTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCAGCTTTGCTGACCCTGCTTGTCAACTCTACGTCTTTGTTTCGTTT

NcoI (561)
BstEII (556)
KasI (536) **AgeI (553)**
 501 TCTGTTCTGGCGGTTACAGATCCAAGCTGTGACCGGGCGCTACCTGAGATCACCGGTcaCCATGGAAATCAAGGTGCTGTTGCCCTCATCTGTATTGC
 1► M E I K V L F A L I C I A

BglII (676)
 601 TGTTGCTGAGCAAACCCACTGAAATCAATGAAGACCTCAATATAGCTGCTGTGGCCTCCAACCTTGCACCACAGATCTTGAGACTGACCTGTTACC
 13► V A E A K P T E I N E D L N I A A V A S N F A T T D L E T D L F T
Bsu36I (800)
 701 AACTGGGAGACCATGAATGTGATTAGCACTGACACAGAGCAGGTGAACACAGATGCTGACAGGGGCAAGCTGCCTGGCAAAAACCTCCCCCAGATGTCC

47► N W E T M N V I S T D T E Q V N T D A D R G K L P G K K L P P D V
 801 TGAGGGAGCTGGAGGCAATGCCAGAAGGGCTGGTGCACAAGGGCTGCCTCATTTGCCTCTCCACATTAAGTGACCCCTAAGTGAAGAAATTTAT

80► L R E L E A N A R R A G C T R G C L I C L S H I K C T P K M K K F I
EcoRV (973)
 901 CCCTGGCAGGTGCCACACTTATGAAGTGAAAAGGAGTCTGCTCAGGGAGGGATTGGAGAGGCAATTGTTGATATCCAGAGATTCCTGGCTTCAAGGAT

113► P G R C H T Y E G E K E S A Q G G I G E A I V D I P E I P G F K D
 1001 AAGGAGCACTGGACAGTTTATTGCTCAAGTGGACCTCTGTGCTGATTGCACCACTGGCTGTCTGAAGGGCCTTGCCAATGTCAGTGTCTGACCTCC

147► K E P L D Q F I A Q V D L C A D C T T G C L K G L A N V Q C S D L
EcoRI (1196)
Acc65I (1190)
 1101 TGAAGAAGTGGCTTCCCAGAGGTGTACCACTTTTCCAGCAAGATTCAGGGTAGGGTGGACAAAATCAAGGGTCTGGCTGGGGACAGAGGTACCGAATT

180► L K K W L P Q R C T T F A S K I Q G R V D K I K G L A G D R G T E F
XhoI (1207) **BglII (1223)**
EcoRV (1204) **NcoI (1215)**
 1201 CGATATCTCGAGCACCATGGTTAGATCTCCAGAGGGCCCAATCAAGCCCTGTCTCCATGCAAATGCCAGCACCTAACCTCTGGGTGGACCATCC
 1► P R G P T I K P C P P C K C P A P N L L G G P S

213► D I S S T M V R S P R G P T I K P C P P C K C P A P N L L G G P S
BspHI (1335) **BspLU11I (1361)**
 1301 GTCTTCATCTTCCCTCCAAGATCAAGGATGACTCATGATCTCCCTGAGCCCATAGTCACATGTGTGGTGGTGGATGTGAGCGAGGATGACCCAGATG
 25► V F I F P P K I K D V L M I S L S P I V T C V V V D V S E D D P D

247► V F I F P P K I K D V L M I S L S P I V T C V V V D V S E D D P D
PvuII (1410) **SalI (1477)**
 1401 TCCAGATCAGCTGGTTTGTGAACAACGTGGAAGTACACACAGCTCAGACACAAACCCATAGAGAGGATTACAACAGTACTCTCCGGTGGTCAAGTGCCTC
 58► V Q I S W F V N N V E V H T A Q T Q T H R E D Y N S T L R V V S A L

280► V Q I S W F V N N V E V H T A Q T Q T H R E D Y N S T L R V V S A L
 1501 CCCATCCAGCACCGAGTGGATGAGTGGCAAGGATTCAAATGCAAGGTCAACAACAAAGACCTCCAGCGCCATCGAGAGAACCATCTCAAACCC
 91► P I Q H Q D W M S G K E F K C K V N N K D L P A P I E R T I S K P

313► P I Q H Q D W M S G K E F K C K V N N K D L P A P I E R T I S K P
SacI (1618)
 1601 AAAGGTCAGTAAGAGCTCCACAGGTATATGCTTGCCTCCACCAGAAGAAGATGACTAAGAAACAGGCTACTCTGACCTGCATGGTCACAGACTTCA
 125► K G S V R A P Q V Y V L P P P E E E M T K K Q V T L T C M V T D F

347► K G S V R A P Q V Y V L P P P E E E M T K K Q V T L T C M V T D F

1701 TGCCTGAAGACATTTACGTGGAGTGGACCAACAACGGGAAAAACAGAGCTAAACTACAAGAACACTGAACCAGTCTGGACTCTGATGGTTCTTACTTCAT
158▶ M P E D I Y V E W T N N G K T E L N Y K N T E P V L D S D G S Y F M

380▶ M P E D I Y V E W T N N G K T E L N Y K N T E P V L D S D G S Y F M
1801 GTACAGCAAGCTGAGAGTGGAAAAGAAGAACTGGGTGGAAAGAAATAGCTACTCTGTTCAGTGGTCCACGAGGGTCTGCACAATCACCACAGCTAAG
191▶ Y S K L R V E K K N W V E R N S Y S C S V V H E G L H N H H T T K

413▶ Y S K L R V E K K N W V E R N S Y S C S V V H E G L H N H H T T K
Sacl (1930) XbaI (1939) Ball (1953)
1901 AGCTTCTCCCGGACTCCGGGTAATGAGCTCAGCTAGGCTAGACCTAGCTGGCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACCTAG
225▶ S F S R T P G K •

447▶ S F S R T P G K •

2001 AATGCAGTGAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAAACAACAACAAATTGC
HpaI (2085)

2101 ATTCAATTTTATGTTTCAGGTTTCAGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTATGGAATTAATCTAAAATACAGCA
AseI (2182)
XmnI (2178)

2201 TAGCAAACTTTAACCTCAAATCAAGCCTCTACTTGAATCCTTTCTGAGGGATGAATAAGGCATAGGCATCAGGGGCTGTGGCAATGTGCATTAGCT

2301 GTTTGAGCCTCACCTCTTTTCATGGAGTTAAGATATAGTGATTTTTCCCAAGGTTTGAAGTACTCTTCATTTCTTTATGTTTTAAATGACTGACCT
SapI (2364)

2401 CCCACATTCCTTTTTAGTAAAATATTCAGAAATAATTAATACATCATTGCAATGAAAATAAATGTTTTTATTAGGCAGAAATCCAGATGCTCAAGGC
SspI (2424) SwaI (2439)

2501 CCTTCATAATATCCCCAGTTTAGTAGTTGGACTTAGGGAACAAAGAACCTTTAATAGAAATGGACAGCAAGAAAGCGAGCTTCTAGCTTATCTCAG
125 ◀ •

2601 TCCTGCTCCTCTGCCACAAAGTGCACGAGTTGCCGCGGGTCCGCGAGGGCGAACTCCCGCCCCACGGCTGCTCGCCGATCTCGGTTCATGGCCGGCC
123◀ D Q E E A V F H V C N G A P D R L A F E R G W P Q E G I E T M A P G
2701 CGGAGGCGTCCCGAAGTTCGTGGACACGACTCCGACCCTCGGCGTACAGCTCGTCCAGGCCGCGCACCCACCCAGGCCAGGGTGTGTCCGGCAC
90◀ S A D R F N T S V V E S W E A Y L E D L G R V W V W A L T N D P V

2801 CACCTGGTCTGGACCGCGTGTGAACAGGGTACGTCGTCGCCGACCACACCGCGAAGTCTGCTCCACGAAGTCCCGGGAACCCCGAGCCGGTCCG
57◀ V Q D Q V A S I F L T V D D R V V G A F D D E V F D R S F G L R D
SexAI (2801) SgrAI (2852) XmaI (2878)
SmaI (2880)

2901 GTCCAGAAGTCCGACCGTCCGGCGACGTCGCGCGCGGTGAGCACCAGGAAACGGCACTGGTCAACTTGGCCATGATGGCTCTCctgtcaggagaggaaaga
23◀ T W F E V A G A V D R A T L V P V A S T L K A M
BsrBI (2919) BssHII (2930) Ball (2967)

3001 gaagaaggttagtacaattgCTATAGTGAGTTGATTATACTATGCAGATATACTATGCCAATGATTAATTGTCAAAGTGGCTGCAGggttcatagtg
AseI (3066) PstI (3088)

3101 ccacttttctgactgccccatctcctgcccccttccaggcatagacagtcagtgacttacCAAAGTACAGGAGGGAGAAGGCAGAAGCTTGAG
HindIII (3192)

3201 ACAGACCCGCGGGACCCGCAACTGCGAGGGGACGTGGCTAGGGCGGCTTCTTTATGTTGCGCGGCCCTCGGAGGCAGGGCGCTCGGGGAGGCTAGC
SacII (3210) StuI (3294)
Eco147I (3294)

3301 GGCCAATCTGCGGTGGCAGGAGGGGGCCGAAGGCCGTGCTGACCAATCCGGAGCACATAGGAGTCTCAGCCCCCGCCCAAAGCAAGGGGAAGTCA
BspEI (3349)

3401 CGCGCCTGTAGCCAGCGTGTGTGAAATGGGGCTTGGGGGTTGGGGCCCTGACTAGTCAAAACAACTCCCAATTGACGTCAATGGGGTGGAGACT
SpeI (3457)

3501 TGGAAATCCCCGTGAGTCAAACCGTATCCACGCCATTGATGTACTGCCAAAACCGCATCATCATGGTAATAGCGATGACTAATACGTAGATGACTGC
SnaBI (3587)

3601 CAAGTAGGAAAGTCCCATAGGTCATGTAAGTGGGCATAATGCCAGGCGGGCCATTTACCGTCAATGACGTCAATAGGGGGCTACTTGGCATATGATACA
NdeI (3691)

3701 CTTGATGTAAGTCCCAAGTGGGCGTTTACCCTAAATACTCCACCCATTGACGTCAATGGAAAGTCCCTATTGGCGTTACTATGGGAACATACGTCATTAT

3801 TGACGTCAATGGGGGGGGTCTTTGGGCGGTGAGCCAGGCGGGCCATTACCGTAAGTTATGTAACGCCTGCAGGTTAATTAAGAACATGTGAGCAAAAG
PacI (3880)
PstI (3873)
SdaI (3873) BspLU11I (3886)

3901 GCCAGAAAAGGCCAGGAACCGTAAAAGGCCGCTTGTGCTGCTTTTCCATAGGCTCCGCCCTGACGAGCATCACAAAATCGACGCTCAAGTCA
4001 GAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGCGTTTCCCCCTGGAAGCTCCCTGTCGCTCTCTGTTCCGACCTGCCGTTACCGGATAC
4101 CTGTCCGCTTTCTCCTTCGGGAAGCGTGGCGTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTGCTTCCGCTCAAGCTGGGCTGTG
4201 TGCACGAACCCCGTTCAGCCGACCGCTGCGCCTTATCCGTAACATATGCTTGTAGTCCAACCGGTAAGACACGACTTATCGCCACTGGCAGCAGC

4301 CACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGT

4401 ATCTGCGCTtgattgcAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGTTTTTTTGTGTTGCA

4501 AGCAGCAGATTACGCGCAGAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGTCTGACGCTCAGTGAACGAAAACTCACGTTAAGGGAT

Swal (4628) EagI (4636)

Pacl (4620)

NotI (4636)

4601 TTTGGTCATGGCTAGTTAATTAACATTTAAATCAGCGGCCGCAATAAAATATCTTTATTTTCATTACATCTGTGTGGTTTTTTGTGTAATCGTAAC

4701 TAACATACGCTCTCCATCAAAACAAAACGAAACAAAACAAACTAGCAAATAGGCTGTCCCAGTGCAAGTGCAGGTGCCAGAACATTTCTCTATCGAA